Professional
Added to YB: 2024-12-10
Pitch date: 2024-11-05
MRK [bullish]
Merck & Co., Inc.
+0.81%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$245.7B
Pitch Price
$99.50
Price Target
N/A
Dividend
3.43%
EV/EBITDA
8.44
P/E
13.10
EV/Sales
4.19
Sector
Pharmaceuticals
Category
growth
The London Company Income Equity Portfolio Holding: Merck & Co., Inc.
MRK: Keytruda drives growth, but HPV vaccine outlook lowered due to China challenges. Mgmt confident in long-term potential outside China. Strong drug/vaccine pipeline & leadership team's ability to accelerate pipeline & pursue M&A opportunities remain attractive. Solid growth in key areas despite headwinds.
Read full article (1 min)